This site is intended for healthcare professionals.

Header Ads

Header Ads

Non Alcoholic Fatty Liver Disease -NAFLD

x

Non Alcoholic Fatty Liver Disease -NAFLD

h

Non-alcoholic fatty liver disease ( NAFLD ) can be diagnosed on the basis of Evidence of hepatic steatosis by imaging or histology Lack of secondary causes of hepatic fat accumulation 
( eg significant alcohol consumption ) ie diagnosis of exclusion

NAFL-NAFL is defined as the presence of 
of > 5 % hepatic steatosis without evidence of hepatocellular injury in
 the form of hepatocyte ballooning

This has a relatively benign course and 
is largely asymptomatic NASH- NASH > 5 % hepatic steatosis – 
this reflects a more profound inflammatory liver damage with presence of lobular inflammation and helatocellular damage ( ballooning )

This carries a worse prognosis with risk of progressive fibrosis leading to cirrhosis and hepatocellular carcinoma

NAFLD is the most common liver disorder in Western countries
Due to rising obesity NAFLD is one of the most important cause of liver disease worldwide in adults and children Estimated to affect atleast 25 % – 30 % of adults in general population and
70-90 % of people with obesity or type 2 diabetes Prevalence of NAFLD has doubled over the past 20 yrs Projected to be leading indication for liver transplant within a decade

Features of metabolic syndrome – including
○ central obesity
○ impaired glucose regulation ( Type 2 diabetes )
○ hypertension
○ hyperlipidemia Obstructive sleep apnoea Polycystic ovary syndrome Hypothyroidism Family h/o NAFLD Male sex Hyperuricemia ( Risk factors and biomarkers of non-alchoholic fatty liver disease : an observational cross-sectional population survey BMJ open Vol 8, Issue 4 ) Nutritional – TPN and refeeding syndromes mrapid weight loss and jejunoileal bypass surgery Drugs eg NSAIDs , amiodarone , corticosteroids , diltiazem , methotrexate , tamoxifen

Mostly detected incidentally following test for Liver function or US 
( increased hepatic echogenicity ) Usually suspected with mild to moderate elevations of serum transaminases with alanine aminotransferase ( ALT ) exceeding those of aspartate aminotransferase ( AST ) GGT and AlkPo4 may also be elevated but PT , Bilirubin , Albumin levels are normal except in NAFLD associated cirrhosis Many patients with NAFLD will be obese asymptomatic and with normal LFTs Gold standard for diagnosis of NAFLD
 is liver biopsy Do not use routine liver blood tests to r/o NAFLD – LFT and US may be normal and not necessarily reflect the stage of disease

Non Invasive Liver Screen- LFT FBC ( eg low platelets ) Clotting screen Hepatitis serology ( B and C ) Auto-antibodies ( eg ANA , ASMA , AMA ) Ferritin – usually mildly elevated
consider transferrin Ceruloplasmin Alpha 1 antitrypsin Immunoglobulins Hba1c Lipid profile , TFT, Renal profile Coeliac screen

Management –No specific drug treatment – NAFL A validated widely accepted procedure for the diagnosis and monitoring of NAFLD does not exist yet Give advice on lifestyle modification eg about
○ diet
○ physical activity
○ exercise
○ weight loss
○ alcohol
 Ensure optimal management of associated conditions as
○ hypertension
○ hyperlipidemia
○ type 2 diabetes

Scoring tests indicated risk of fibrosis
Several score available as

○ NAFLD fibrosis score
○ Enhanced Liver Fibrosis
○ FIB4 
○ BARD
 Abnormal blood results as
○ raised immunoglobulins
○ hepatitis B or C
○ ↑↑ ferritin and transferrin ( iron overload )
○ Autoantibody testing +ve
○ Low ceruloplasmin 
○ Low alpha 1 antitrypsin


References ; Further reading

 EASL-EAS-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease Journal of Hepatology 2016 vol .64 1388-1402 Non-alcoholic fatty liver disease ( NAFLD ) : assessment and management NICE guideline NG 49 July 2016 The Diagnosis and Management of Non-alcholic Fatty Liver Disease ; Practice Guidance From the American association for the study of Liver Diseases Naga Chalasani et al HEPATOLOGY PRACTICE GUIDANCE HEPATOLOGY VOL 67 ,NO. 1 , 2018 Non-Alcoholic fatty liver disease in 2016 S.A Townsend et al British Medical Bulletin , 2016 , 116: 143-156 Non-alcoholic fatty liver disease ( NAFLD ) : summary of NICE guidance BMJ 2012; 354 :i14428 Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults BMJ 2018; 362: k2734 Global burden of NAFLD and NASH : trends , predictions , risk factors and prevention Zobair Younossi et al Nature Reviews Gastroenterology & Hepatology Volume 15 January 2018 CKS NHS Non-alcoholic fatty liver disease ( NAFLD ) Last revised in September 2016 Non-alcoholic fatty liver disease Brent A Neuschwander-Tetri BMC Medicine ( 2017 ) http://www.nafldscore.com/

 

Related Topics

Comments - to make a comment on the above chart please log in.


Register

START TYPING AND PRESS ENTER TO SEARCH